BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24522743)

  • 1. Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.
    Takeuchi H; Saeki T; Aiba K; Tamura K; Aogi K; Eguchi K; Okita K; Kagami Y; Tanaka R; Nakagawa K; Fujii H; Boku N; Wada M; Akechi T; Udagawa Y; Okawa Y; Onozawa Y; Sasaki H; Shima Y; Shimoyama N; Takeda M; Nishidate T; Yamamoto A; Ikeda T; Hirata K
    Int J Clin Oncol; 2016 Feb; 21(1):1-12. PubMed ID: 26081252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow R; Ruhlmann CH; Garcia-Del-Barrio MA; Schwartzberg L; Rapoport BL; Jahn F
    Support Care Cancer; 2023 Dec; 32(1):37. PubMed ID: 38110581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and efficacy of chemoimmunotherapy when administered with a corticosteroid-free anti-emetic regimen.
    Tieri J; Harris B; Melikian L; Bullington S; Naville-Cook C; Crawford B
    J Oncol Pharm Pract; 2023 Oct; 29(7):1661-1666. PubMed ID: 36544380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Ruhlmann CH; Sayegh P; Hesketh PJ
    Support Care Cancer; 2023 Dec; 32(1):53. PubMed ID: 38129530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticipatory prescribing in community end-of-life care.
    Lee C; Tran TT; Ross J
    BMJ Support Palliat Care; 2023 Oct; ():. PubMed ID: 37852662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.
    Kobayashi M; Kako J; Iba A; Okuyama A; Ozawa K; Abe M; Wada M; Akechi T; Iihara H; Imamura CK; Kim YI; Sasaki H; Satomi E; Takeda M; Tanaka R; Nakajima TE; Nakamura N; Nishimura J; Noda M; Hayashi K; Higashi T; Boku N; Matsumoto K; Matsumoto Y; Okita K; Yamamoto N; Aogi K; Iino K
    Int J Clin Oncol; 2024 May; ():. PubMed ID: 38722486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study.
    Yaguchi-Saito A; Kaji Y; Matsuoka A; Okuyama A; Fujimori M; Saito J; Odawara M; Otsuki A; Uchitomi Y; Zenda S; Shimazu T
    BMJ Open; 2022 Jun; 12(6):e055473. PubMed ID: 35667723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world emetic risk of chemotherapy and the corresponding antiemetic therapy in Japan: A study based on a nationwide database.
    Okuyama A; Boku N; Higashi T
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1482. PubMed ID: 34176233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China.
    Zong X; Zhang J; Ji X; Gao J; Ji J
    Chin J Cancer Res; 2016 Apr; 28(2):168-79. PubMed ID: 27199514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
    Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
    Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
    Okuyama A; Nakamura F; Higashi T
    JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
    BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.